Ellington Management Group’s Iovance Biotherapeutics IOVA Stock Holding History

Ellington Management Group’s Portfolio IOVA Stock Details IOVA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q2	–	Sell	-25,394	Closed	-$241K	–	677
2019 Q1	$241K	Buy	+25,394	New	+$247K	0.04%	424
2018 Q1	–	Sell	-19,200	Closed	-$154K	–	919
2017 Q4	$154K	Buy	19,200 +5,400	+39%	+$43.4K	0.03%	524
2017 Q3	$107K	Sell	13,800 -17,800	-56%	-$113K	0.02%	585
2017 Q2	$232K	Buy	+31,600	New	+$201K	0.03%	489
2016 Q4	–	Sell	-12,400	Closed	-$102K	–	666
2016 Q3	$102K	Buy	+12,400	New	+$105K	0.03%	614
2016 Q2	–	Sell	-34,600	Closed	-$176K	–	363
2016 Q1	$176K	Buy	+34,600	New	+$189K	0.08%	419

Other funds holding IOVA

Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

CCM

Consonance Capital Management New York $7.28M AUM 43.59% 1-Year Est. Return

FCM

Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return

OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return

GPP

Great Point Partners Greenwich, Connecticut $529M AUM 337.4% 1-Year Est. Return

Ellington Management Group's IOVA Position: Q2 2019 in Review

Ellington Management Group sold out of Iovance Biotherapeutics (IOVA) in Q2 2019, closing a stake of 25,394 shares — an estimated $241K sold.

Ellington Management Group first reported a position in IOVA in Q1 2016 and held it in 6 quarters. The position peaked at $241K in Q1 2019. 167 funds tracked by Wall St. Rank hold IOVA as of Q2 2019.

Ellington Management Group reported no remaining Iovance Biotherapeutics position as of Q2 2019 after selling out during the quarter.
Ellington Management Group sold 25,394 Iovance Biotherapeutics shares in Q2 2019, an estimated $241K.
Ellington Management Group first reported a position in Iovance Biotherapeutics in Q1 2016 and held it in 6 quarters.
Ellington Management Group's Iovance Biotherapeutics position peaked at $241K in Q1 2019.
167 funds tracked by Wall St. Rank held Iovance Biotherapeutics as of Q2 2019.

Based on Ellington Management Group's 13F filing for Q2 2019, filed 14 Aug 2019.